BACKGROUND: The adeno-associated virus (AAV) has many safety features that favor its use in the treatment of arthritic conditions; however, the conventional, single-stranded vector is inefficient for gene delivery to fibroblastic cells that primarily populate articular tissues. This has been attributed to the inability of these cells to convert the vector to a double-stranded form. To overcome this, we evaluated double-stranded self-complementary (sc) AAV as a vehicle for intra-articular gene delivery. METHODS: Conventional and scAAV vectors were used to infect lapine articular fibroblasts in culture to determine transduction efficiency, transgene expression levels, and nuclear trafficking. scAAV containing the cDNA for interleukin (IL)-1 receptor antagonist (Ra) was delivered to the joints of naïve rabbits and those with IL-1beta-induced arthritis. From lavage of the joint space, levels of transgenic expression and persistence were measured by enzyme-linked immunosorbent assay. Infiltrating leukocytes were quantified using a hemocytometer. RESULTS: Transgene expression from scAAV had an earlier onset and was approximately 25-fold greater than conventional AAV despite the presence of similar numbers of viral genomes in the nuclei of infected cells. Fibroblasts transduced with scAAV produced amounts of IL1-Ra comparable to those transduced with adenoviral and lentiviral vectors. IL1-Ra was present in lavage fluid of most animals for 2 weeks in sufficient quantities to inhibit inflammation of the IL-1beta-driven model. Once lost, neither subsequent inflammatory events, nor re-administration of the virus could re-establish transgene expression. CONCLUSIONS: scAAV-mediated intra-articular gene transfer is robust and similarly efficient in both normal and inflamed joints; the resulting transgenic expression is sufficient to achieve biological relevance in joints of human proportion. 2009 John Wiley & Sons, Ltd.
BACKGROUND: The adeno-associated virus (AAV) has many safety features that favor its use in the treatment of arthritic conditions; however, the conventional, single-stranded vector is inefficient for gene delivery to fibroblastic cells that primarily populate articular tissues. This has been attributed to the inability of these cells to convert the vector to a double-stranded form. To overcome this, we evaluated double-stranded self-complementary (sc) AAV as a vehicle for intra-articular gene delivery. METHODS: Conventional and scAAV vectors were used to infect lapine articular fibroblasts in culture to determine transduction efficiency, transgene expression levels, and nuclear trafficking. scAAV containing the cDNA for interleukin (IL)-1 receptor antagonist (Ra) was delivered to the joints of naïve rabbits and those with IL-1beta-induced arthritis. From lavage of the joint space, levels of transgenic expression and persistence were measured by enzyme-linked immunosorbent assay. Infiltrating leukocytes were quantified using a hemocytometer. RESULTS: Transgene expression from scAAV had an earlier onset and was approximately 25-fold greater than conventional AAV despite the presence of similar numbers of viral genomes in the nuclei of infected cells. Fibroblasts transduced with scAAV produced amounts of IL1-Ra comparable to those transduced with adenoviral and lentiviral vectors. IL1-Ra was present in lavage fluid of most animals for 2 weeks in sufficient quantities to inhibit inflammation of the IL-1beta-driven model. Once lost, neither subsequent inflammatory events, nor re-administration of the virus could re-establish transgene expression. CONCLUSIONS: scAAV-mediated intra-articular gene transfer is robust and similarly efficient in both normal and inflamed joints; the resulting transgenic expression is sufficient to achieve biological relevance in joints of human proportion. 2009 John Wiley & Sons, Ltd.
Authors: S C Ghivizzani; E R Lechman; R Kang; C Tio; J Kolls; C H Evans; P D Robbins Journal: Proc Natl Acad Sci U S A Date: 1998-04-14 Impact factor: 11.205
Authors: E Lubberts; L A Joosten; L van Den Bersselaar; M M Helsen; A C Bakker; J B van Meurs; F L Graham; C D Richards; W B van Den Berg Journal: J Immunol Date: 1999-10-15 Impact factor: 5.422
Authors: James M K Chan; Gilda Villarreal; Wen Wen Jin; Tony Stepan; Haim Burstein; Sharon M Wahl Journal: Mol Ther Date: 2002-12 Impact factor: 11.454
Authors: L R Goodrich; J C Grieger; J N Phillips; N Khan; S J Gray; C W McIlwraith; R J Samulski Journal: Gene Ther Date: 2015-04-23 Impact factor: 5.250
Authors: Katherine A Glass; Jarrett M Link; Jonathan M Brunger; Franklin T Moutos; Charles A Gersbach; Farshid Guilak Journal: Biomaterials Date: 2014-04-22 Impact factor: 12.479
Authors: Kaitlyn L Moss; Zibin Jiang; Michael E Dodson; Renata L Linardi; Joanne Haughan; Alexis L Gale; Cara Grzybowski; Julie E Engiles; Darko Stefanovski; Mary A Robinson; Kyla F Ortved Journal: Hum Gene Ther Date: 2019-12-18 Impact factor: 5.695
Authors: Daniele Bellavia; F Veronesi; V Carina; V Costa; L Raimondi; A De Luca; R Alessandro; M Fini; G Giavaresi Journal: Cell Mol Life Sci Date: 2017-09-01 Impact factor: 9.261
Authors: Hannah H Lee; Michael J O'Malley; Nicole A Friel; Karin A Payne; Chunping Qiao; Xiao Xiao; Constance R Chu Journal: Hum Gene Ther Date: 2013-04 Impact factor: 5.695